Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer

NCT05079074 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 223

Last updated 2022-06-22

No results posted yet for this study

Summary

This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) application in late-stage breast cancers.

Conditions

Interventions

DIAGNOSTIC_TEST

ctDNA testing

ctDNA testing was performed for late-stage metastatic breast cancer patients to trace their ctDNA abnormality.

Sponsors & Collaborators

  • Hunan Cancer Hospital

    lead OTHER

Principal Investigators

  • Quchang Ouyang, MD · Hunan Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-01
Primary Completion
2019-06-30
Completion
2021-06-30

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05079074 on ClinicalTrials.gov